About Genocea

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea is exploring strategic alternatives for GEN-003, its Phase 3-ready immunotherapy candidate for the treatment of genital herpes.

adjusted-apc-t-cell-image2

Stock Quote

NASDAQ GNCA
$0.80
- 0.28 (-25.83%)


1.40M

Volume

$0.83

Day High

$0.79

Day Low

Jan 17, 2018 ET on 9:39 AM Delayed at least 20 minutes.

Stock Chart